Organization & Developments: ENDRA Life Sciences

Parents

2011: Endra Life Sciences Launches First Ever Commercial Photoacoustic 3-D Tomographic Imaging System (2011)
2020: ENDRA Life Sciences' NASH Test Device, TAEUS, At Commercialization Inflection Point
2022: United States Patent and Trademark Office (USPTO) has issued two new ENDRA patents covering a method for manufacturing a radio frequency applicator and a system for monitoring tissue temperature.
ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound.
Launched the Nexus 128, a preclinical photoacoustic computed tomography (CT) scanner for small animal imaging.
The Nexus 128 makes in vivo quantification of tumor vasculature possible without the need for contrast agents and helps preclinical researchers gain deeper insight into areas such as how drugs treat disease and cancer progression, without ionizing radiatio
The system is used for simple, fast, non-invasive quantification of tumor vasculature and other physiological parameters for preclinical research.